Amendment: Tagrisso significantly improves overall survival
The following amendment(s) has (have) been made to the 'Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer' announcement released on 09 August 2019 at 07:00 BST. Correction: Tagrisso 40mg and 80mg once-daily oral tablets are not approved in China for 1st-line EGFRm advanced NSCLC. Tagrisso has received approval in more than 70 countries, including the US, Japan and the EU, for 1st-line EGFRm advanced NSCLC, and in more than 80 countries, including the US, Japan, China and the EU, for 2nd-line use in